Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 14/20 | 0.77 |
| ▸ | CDK2 | P24941 | 10/20 | 0.77 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.77 |
| ▸ | CCNH | P51946 | 8/20 | 0.77 |
| ▸ | MNAT1 | P51948 | 7/20 | 0.77 |
| ▸ | CDK1 | P06493 | 7/20 | 0.77 |
| ▸ | CDK4 | P11802 | 4/20 | 0.77 |
| ▸ | CDK9 | P50750 | 4/20 | 0.77 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.77 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.77 |
| ▸ | CDK8 | P49336 | 3/20 | 0.77 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | CCND1 | P24385 | 2/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | INSRR | P14616 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24793474 | 0.95 | CDK7 (0.70) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL24792386 | 0.90 | CDK7 (0.64) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL24791465 | 0.90 | CDK7 (0.64) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL30083625 | 0.90 | CDK7 (0.64) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL24791462 | 0.89 | CDK7 (0.63) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL24792712 | 0.89 | CDK2 (0.63) | CDK7CDK2CCNE1CCNHMNAT1 | |
| SCHEMBL24792393 | 0.88 | CDK7 (0.61) | CDK7CDK2CCNE1CCNHMNAT1 | |
| Ct-7001 SCHEMBL20016238 | 0.87 | CDK7 (1.00) | CDK7CDK2CCNE1CCNHMNAT1 | |
| Ct-7001 SCHEMBL20848165 | 0.87 | CDK7 (1.00) | CDK7CDK2CCNE1CCNHMNAT1 | |
| Ct-7001 SCHEMBL17032274 | 0.87 | CDK7 (1.00) | CDK7CDK2CCNE1CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | Carrick Therapeutics Limited (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | Carrick Therapeutics Limited (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | Carrick Therapeutics Limited (IE) | 2024-01-02 | — | — | US | disclosed |
| CN-111566106-B | Compounds as CDK inhibitors | 卡里克治疗有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-3684769-B1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | CARRICK THERAPEUTICS LTD (IE) | 2022-01-12 | — | — | EP | disclosed |
| EP-3684769-B1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | CARRICK THERAPEUTICS LTD (IE) | 2022-01-12 | — | — | EP | disclosed |
| US-20200345736-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | Carrick Therapeutics Limited (IE) | 2020-11-05 | — | — | US | disclosed |
| US-20200345736-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | Carrick Therapeutics Limited (IE) | 2020-11-05 | — | — | US | disclosed |
| CN-111566106-A | 4- [ [ (7-aminopyrazolo [1,5-a ] pyrimidin-5-yl) amino ] methyl ] piperidin-3-ol compounds as CDK inhibitors | 卡里克治疗有限公司 | 2020-08-21 | — | — | CN | disclosed |
| WO-2019057825-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | Carrick Therapeutics Limited (IE) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345736-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | CDK10, CDK1, CDK20 | CDK7 21/4885CDK2 6/4885CCNE1 50/4885 |
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | CDK10, CDK1, CDK20 | CDK7 21/4885CDK2 6/4885CCNE1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.